异位性皮肤炎治疗市场规模、份额和成长分析（按给药途径、药物类别、分销管道和地区划分）—产业预测，2026-2033年

预计到 2024 年，全球异位性皮肤炎药物市场规模将达到 162.8 亿美元，到 2025 年将达到 177.8 亿美元，到 2033 年将达到 359.5 亿美元，在预测期（2026-2033 年）内复合年增长率为 9.2%。

全球异位性皮肤炎治疗市场洞察

推动全球异位性皮肤炎治疗市场发展的因素

受环境变化、都市化以及遗传因素导致异位性皮肤炎盛行率上升（尤其是在儿童对异位性皮肤炎的认识不断提高，以及医疗系统致力于改进治疗方法，针对这种慢性皮肤病的创新药物的需求预计将进一步增长，最终影响市场动态，并推动该领域的进一步研发。

限制全球异位性皮肤炎治疗市场的因素

由于各种治疗方法的副作用，全球异位性皮肤炎药物市场面临严峻挑战。虽然某些全身性免疫抑制剂疗效显着，但它们也可能导致严重的併发症，例如感染疾病和肝毒性，引发人们对患者长期用药安全的担忧。这些不良反应会降低患者的生活质量，并最终阻碍异位性皮肤炎药物市场的成长潜力。随着越来越多的患者和医疗保健提供者权衡这些药物的风险和益处，异位性皮肤炎药物的整体接受度和使用率可能会受到影响，从而限制市场扩张。

异位性皮肤炎治疗市场的全球趋势

由于JAK（ Janus激酶）抑制剂能够快速缓解症状并有效满足患者未被满足的需求，全球异位性皮肤炎治疗市场正日益采用此类药物。以Upadacitinib和abrocitinib为代表的这些创新治疗方法，因其在控制异位性皮肤炎症状方面的有效性而备受关注，有助于提高患者的生活品质。随着市场的发展，对JAK抑制剂的策略关注预计将显着改变竞争格局，为製药企业提供新的成长和扩张机会，同时满足皮肤病学领域对有效治疗方案日益增长的需求。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

全球异位性皮肤炎治疗市场规模（按产品类型和复合年增长率划分）（2026-2033 年）

• 生物製药
• 其他的

全球异位性皮肤炎治疗市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• 皮质类固醇
• Calcineurin抑制剂
• PDE4抑制剂
• 生物製药
• 其他的

全球异位性皮肤炎治疗市场规模（按疗法和复合年增长率划分）（2026-2033 年）

• 照光治疗
• 定向疗法

全球异位性皮肤炎治疗市场规模（按给药管道和复合年增长率划分）（2026-2033 年）

• 外用药物
• 肠外
• 口服

全球异位性皮肤炎治疗药物市场规模（按分销类型划分）及复合年增长率（2026-2033 年）

• 医院药房
• 零售药房
• 其他药房

全球异位性皮肤炎治疗药物市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Astellas Pharma Inc.（Japan）
• Bayer AG（Germany）
• Allergan plc（Ireland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Sanofi SA（France）
• Incyte Corporation（USA）
• AbbVie Inc.（USA）
• Galderma SA（Switzerland）
• Leo Pharma A/S（Denmark）
• Eli Lilly and Company（USA）
• Amgen Inc.（USA）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Bristol-Myers Squibb Company（USA）
• Almirall, SA（Spain）
• Sun Pharmaceutical Industries Ltd.（India）

结论与建议

Global Atopic Dermatitis Drugs Market size was valued at USD 16.28 Billion in 2024 and is poised to grow from USD 17.78 Billion in 2025 to USD 35.95 Billion by 2033, growing at a CAGR of 9.2% during the forecast period (2026-2033).

Market insights for Global Atopic Dermatitis Drugs market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atopic Dermatitis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Atopic Dermatitis Drugs Market Segments Analysis

Global Atopic Dermatitis Drugs Market is segmented by Product Type, Drug Class, Therapy, Route of Administration, Distribution and region. Based on Product Type, the market is segmented into Biologics and Others. Based on Drug Class, the market is segmented into Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics and Others. Based on Therapy, the market is segmented into Photo Therapy and Directed Therapy. Based on Route of Administration, the market is segmented into Topical, Parenteral and Oral. Based on Distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Other Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Atopic Dermatitis Drugs Market

The global market for atopic dermatitis drugs is experiencing growth driven by an increasing prevalence of the condition attributed to environmental changes, urbanization, and genetic factors. This rise in incidence is particularly notable among children and young adults, contributing to a heightened demand for effective therapeutic solutions. As awareness of atopic dermatitis expands and healthcare systems focus on improving treatment options, the need for innovative drugs tailored to manage this chronic skin condition is expected to strengthen, ultimately influencing market dynamics and encouraging further research and development in this field.

Restraints in the Global Atopic Dermatitis Drugs Market

The global market for atopic dermatitis drugs faces significant challenges due to the side effects associated with various treatments. Certain systemic immunosuppressants, while effective, can lead to serious complications such as infections or liver toxicity, raising concerns about long-term patient safety. These adverse effects can negatively impact patients' quality of life, ultimately hindering the growth potential of the atopic dermatitis drugs market. As more patients and healthcare providers weigh the benefits against the risks of these medications, the overall acceptance and utilization of atopic dermatitis drugs may be adversely affected, creating a restraint in market expansion.

Market Trends of the Global Atopic Dermatitis Drugs Market

The Global Atopic Dermatitis Drugs market is increasingly leaning toward the adoption of JAK (Janus kinase) inhibitors due to their ability to provide rapid symptom relief and effectively address the unmet needs of patients. These innovative treatments, exemplified by drugs like upadacitinib and abrocitinib, are gaining prominence for their efficacy in managing atopic dermatitis symptoms, thereby enhancing patient quality of life. As the market evolves, a strategic focus on JAK inhibitors is expected to significantly shape the competitive landscape, offering drug providers new opportunities for growth and expansion while meeting the rising demand for effective therapeutic solutions in dermatology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Atopic Dermatitis Drugs Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Biologics
• Others

Global Atopic Dermatitis Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

Global Atopic Dermatitis Drugs Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Photo Therapy
• Directed Therapy

Global Atopic Dermatitis Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Topical
• Parenteral
• Oral

Global Atopic Dermatitis Drugs Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies

Global Atopic Dermatitis Drugs Market Size & CAGR (2026-2033)

• North America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • US
  • Canada
• Europe (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations